Compare Applied Materials, Inc. (AMAT) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Applied Materials, Inc. vs Crispr Therapeutics AG — how do they compare? Applied Materials, Inc. trades at $552.65 (market cap $417.31B), while Crispr Therapeutics AG trades at $54.02 (market cap $5.23B). The key difference: Applied Materials, Inc. is far larger — about 79.8× Crispr Therapeutics AG's market cap, and Applied Materials, Inc. pays a 0.4% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| AMAT | CRSP | |
|---|---|---|
Market Cap | $417.31B | $5.23B |
Sector | Technology | Health |
52-Week High | $723.00 | $76.78 |
52-Week Low | $156.25 | $44.34 |
Enterprise Value | $416.34B | $3.65B |
Dividend Yield | 0.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMAT trades at $525.61, up 0.67% in the last session, with a neutral technical signal and strong fundamentals. Recent earnings consistently beat expectations, with Q1 2026 EPS of $2.86 surpassing the $2.68 estimate. The stock benefits from robust profitability, including a 48.96% gross margin and 29.31% net margin, amid AI-driven semiconductor demand highlighted by CEO Gary Dickerson on CNBC on May 28, 2026.
Outlook remains positive with a consensus price target of $662.82, implying 26% upside, supported by 40 buy ratings and no sells. Risks include high valuation multiples like a P/E of 49.45 and cyclical semiconductor exposure, but growth in AI and data center investments offers significant opportunity.
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applied Materials, Inc.
Applied Materials is the world's largest supplier of semiconductor manufacturing equipment, providing materials engineering solutions to help make nearly every chip in the world. The firm's systems are used in nearly every major process step with the exception of lithography. Key tools include those for chemical and physical vapor deposition, etching, chemical mechanical polishing, wafer- and reticle-inspection, critical dimension measurement, and defect-inspection scanning electron microscopes.
Read more on AMAT →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
